Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.83 - $3.94 $3,962 - $5,516
1,400 Added 6.25%
23,800 $87,000
Q2 2024

Aug 15, 2024

SELL
$3.06 - $5.58 $38,250 - $69,750
-12,500 Reduced 35.82%
22,400 $74,000
Q1 2024

May 07, 2024

BUY
$2.03 - $6.59 $49,531 - $160,796
24,400 Added 232.38%
34,900 $148,000
Q4 2023

Feb 14, 2024

SELL
$1.4 - $2.09 $18,340 - $27,378
-13,100 Reduced 55.51%
10,500 $18,000
Q3 2023

Nov 14, 2023

SELL
$1.6 - $2.78 $6,080 - $10,564
-3,800 Reduced 13.87%
23,600 $46,000
Q2 2023

Aug 11, 2023

BUY
$2.46 - $4.07 $67,404 - $111,518
27,400 New
27,400 $70,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $146M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.